

# STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (EF-154) DASIGLUCAGON

PRONUNCIATION das" i gloo' ka gon

THERAPEUTIC CLAIM Treatment of hypoglycemia in Type 1 and Type 2 Diabetes patients

## CHEMICAL NAMES


1. L-Threonine, L-histidyl-L-seryl-L-glutaminyglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L- $\alpha$ -aspartyl-L-tyrosyl-L-seryl-L-lysyl-L-tyrosyl-L-leucyl-L- $\alpha$ -aspartyl-2-methylalanyl-L-alanyl-L-arginyl-L-alanyl-L- $\alpha$ -glutamyl-L- $\alpha$ -glutamyl-L-phenylalanyl-L-valyl-L-lysyl-L-tryptophyl-L-leucyl-L- $\alpha$ -glutamyl-L-seryl-
2. [16-(2-methylalanine)(S>X),17-L-alanine(R>A),20-L- $\alpha$ -glutamyl(Q>E),21-L- $\alpha$ -glutamyl(D>E),24-L-lysyl(Q>K),27-L- $\alpha$ -glutamyl(M>E),28-L-serine(N>S)]human glucagon

## STRUCTURAL FORMULA

HSQGTFTSDY SKYLDXARAE EFVKWLEST

Modified residue

$\underline{X}(16)$   
2-methylalanine (Aib)  
(aminoisobutyric acid)



MOLECULAR FORMULA  $C_{152}H_{222}N_{38}O_{50}$

MOLECULAR WEIGHT 3381.61 Da

TRADEMARK None as yet

SPONSOR Zealand Pharma A/S

CODE DESIGNATIONS ZP4207

CAS REGISTRY NUMBER 1544300-84-6

UNII AD4J2O47FQ

WHO NUMBER 10480

## SCS